Caron Jacobson, MD

Articles

Considerations for Selection and Use of Frontline Therapy in Mantle Cell Lymphoma

December 23rd 2021

Shared insight on the optimal selection and use of frontline therapy for patients who present with mantle cell lymphoma.

An Overview of Mantle Cell Lymphoma and Frontline Therapy

December 23rd 2021

Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.

Dr. Jacobson on the Significance of CD19-Targeted CAR T-Cell Therapy in B-Cell Malignancies

October 27th 2020

Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

Dr. Jacobson on FDA Approval of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

October 26th 2020

Caron Jacobson, MD, discusses the approval of brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Jacobson on the ZUMA-5 Trial With Axi-Cel in High-Risk Relapsed/Refractory iNHL

September 2nd 2020

Caron Jacobson, MD, discusses the high-risk patient population within relapsed/refractory indolent non-Hodgkin lymphoma included in the phase 2 ZUMA-5 study.

Dr. Jacobson on the Interim Analysis of the MZL Cohort in the ZUMA-5 Trial

August 11th 2020

Caron Jacobson, MD, discusses the interim analysis results of the marginal zone lymphoma cohort in the phase 2 ZUMA-5 study with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Jacobson on the Next Steps With Axi-Cel in R/R Indolent Non-Hodgkin Lymphoma

June 29th 2020

Caron Jacobson, MD, discusses the next steps with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Jacobson on Design of ZUMA-5 Trial in R/R Indolent Non-Hodgkin Lymphoma

June 18th 2020

Caron Jacobson, MD, discusses the design of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma

June 11th 2020

Caron Jacobson, MD, discusses the benefit of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory follicular lymphoma.

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma

June 10th 2020

Caron Jacobson, MD, discusses the benefit of axicabtagene ciloleucel (Yescarta) in patients with relapsed/refractory follicular lymphoma.

Dr. Jacobson on the Safety Profile of Axi-Cel in Relapsed/Refractory Indolent Lymphoma

June 5th 2020

Caron Jacobson, MD, discusses the safety profile of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.